COVID-19–associated multisystem inflammatory syndrome in children

Summary

COVID-19–associated multisystem inflammatory syndrome in children (MONDO:0100163) is a disease and 21 clinical trials. Top therapeutic interventions include sulfur hexafluoride, blood, whole, and larazotide acetate. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	COVID-19–associated multisystem inflammatory syndrome in children
Mondo ID	MONDO:0100163
DOID	DOID:0080711
NCIT	C172127
GARD	0026069
Is cancer (heuristic)	no

Also known as: COVID-19 -related paediatric inflammatory multisystem syndrome · COVID-19 -related pediatric inflammatory multisystem syndrome · COVID-19 associated multisystem inflammatory syndrome in children · COVID-19 Kawasaki-like syndrome · MIS-C · multisystem inflammatory syndrome in children · multisystem inflammatory syndrome in children associated with coronavirus disease 2019 · multisystem inflammatory syndrome in children associated with COVID-19 · paediatric inflammatory multisystem syndrome · paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 · paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 · paediatric multi-system inflammatory syndrome potentially associated with COVID-19 · paediatric multisystem inflammatory syndrome · pediatric inflammatory multisystem syndrome · pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 · pediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 · pediatric multi-system inflammatory syndrome potentially associated with COVID-19 · pediatric multisystem inflammatory syndrome · PIMS · PIMS-TS (+2 more)

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › COVID-19–associated multisystem inflammatory syndrome in children

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	18
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04640038	PHASE3	COMPLETED	Contrast Enhanced Ultrasound in COVID-19
NCT05022303	PHASE2	TERMINATED	AT1001 for the Treatment of COVID-19 Related MIS-C
NCT04549285	PHASE1	WITHDRAWN	Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome
NCT04278404	Not specified	RECRUITING	Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04844242	Not specified	RECRUITING	MISC COVID-19 Study in Pediatric Population
NCT05287412	Not specified	ACTIVE_NOT_RECRUITING	Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
NCT05582512	Not specified	RECRUITING	Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan
NCT06110975	Not specified	ACTIVE_NOT_RECRUITING	Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)
NCT06887881	Not specified	RECRUITING	PIMS vs PGT-A in Infertile PCOS Patients
NCT07126028	Not specified	ENROLLING_BY_INVITATION	Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
NCT04347408	Not specified	COMPLETED	Seroprevalence of SARS-Cov-2 Antibodies in Children
NCT04588363	Not specified	COMPLETED	COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
NCT04761913	Not specified	COMPLETED	Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic
NCT05186597	Not specified	UNKNOWN	Incidence of MIS-C and Other Complications Following SARS-CoV-2 Infection
NCT05334134	Not specified	UNKNOWN	COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
NCT05382234	Not specified	UNKNOWN	Multisystem Inflammatory Syndrome In Children at Sohag University Hospital
NCT05388396	Not specified	COMPLETED	PIMS-TS in Intensive Care: Retrospective Cohort Trial
NCT05576714	Not specified	UNKNOWN	Investigation of Prognostic Biomarkers, Host Factors and Viral Factors for COVID-19 in Children
NCT05722717	Not specified	UNKNOWN	Genetic Risk Factors for Multi-system Inflammatory Syndrome in Children and Pediatric Post COVID Condition
NCT05911386	Not specified	UNKNOWN	Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
NCT06255860	Not specified	COMPLETED	COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SULFUR HEXAFLUORIDE	4	1
BLOOD, WHOLE	3	1
LARAZOTIDE ACETATE	3	1